Alumis Posts Phase 3 Psoriasis Results for Envudeucitinib Alumis said on Mar 28, 2026 its Phase 3 trial for envudeucitinib met the primary endpoint at Week 12; full PASI and safety tables will be released in coming weeks.

Alumis Posts Phase 3 Psoriasis Results for Envudeucitinib: Alumis said on Mar 28, 2026 its Phase 3 trial for envudeucitinib met the primary endpoint at Week 12; full PASI and safety tables will be released in… 👈 Read full analysis #Psoriasis #ClinicalTrials #Envudeucitinib #Phase3Trials #Dermatology

AstraZeneca raises guidance on stellar cancer drugs growth AZ reports strong financial results for 2025, and provides a first peek at the data for its oral GLP-1 contender elecoglipron

#AstraZeneca #PascalSoriot #cancertherapies #oncologyproducts #commercialperformance #blockbusterbrands #cancer #weightloss #genetherapies #antiHER2therapy #prostatecancer #breastcancer #asthma #respiratorysyncytialvirus #RSV #RSVprophylactic #lupus #phase2trials #phase3trials
zurl.co/yLEDf

Regeneron advances allergy pipeline with positive Phase 3 trial results Investing.com -- Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced positive results from two Phase 3 trials evaluating first-in-class antibody-blockers targeting cat and birch allergies. The pharmaceutical company reported that both trials successfully met their primary and secondary endpoints. The combination therapy was well-tolerated with no serious adverse events reported during the studies. Following these encouraging results, Regeneron plans to advance its allergy pipeline with additional Phase 3 development scheduled to begin in the first half of 2026. The trials represent progress in Regeneron’s efforts to develop novel treatments for common allergies using antibody-blocking technology, potentially offering new options for allergy sufferers. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. Is REGN part of an AI-powered winning strategy? ProPicks AI evaluates REGN alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if REGN is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?

Click Subscribe #Regeneron #AllergyResearch #Phase3Trials #Pharmaceuticals #ClinicalTrials

Gilead's twice-yearly PrEP drug is cleared by FDA Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?

#PrEP #PrEP #FDA #GileadSciences #HIV #USA #preexposureprophylaxis #PrEP #HIVpreexposureprophylaxis #Yeztugo #phase3trials #PURPOSE1 #PURPOSE2 #HIVprevention #Truvada #PrEPmarket #emtricitabinetenofoviralafenamide #PrEPusers #HIVfunding #Prep4All
pharmaphorum.com/news/gileads...

Vera Therapeutics shares soar on positive Phase 3 trial results Investing.com -- Shares of Vera Therapeutics , Inc. (NASDAQ:VERA) surged 80% following the announcement of positive results from its ORIGIN Phase 3 trial of atacicept, a potential treatment for immunoglobulin A nephropathy (IgAN). The company reported that atacicept met the primary endpoint in the trial, achieving a significant 46% reduction in proteinuria compared to baseline and a 42% reduction compared to placebo at week 36. The trial’s success has been a critical driver for the stock’s movement, as the results suggest a promising future for the drug and its potential impact on IgAN treatment. The safety profile of atacicept was also favorable and comparable to placebo, which is an important consideration in the drug’s development and regulatory approval process. Vera Therapeutics plans to engage with the FDA in the coming weeks to discuss the trial results and the regulatory pathway forward. The company’s goal is to submit a Biologics License Application (BLA) for accelerated approval in the fourth quarter of 2025. If approved, atacicept could be launched commercially in the United States in 2026. The ORIGIN Phase 3 trial is a global, multicenter, randomized, double-blind, placebo-controlled study involving 431 adults with IgAN. Participants received atacicept 150 mg through self-administered weekly subcutaneous injections or a placebo. The trial is set to continue in a placebo-controlled blinded manner to further evaluate the change in kidney function over two years, with results expected to be completed in 2027. The company’s CEO, Marshall Fordyce, M.D., expressed optimism about atacicept’s potential to advance the standard of care for IgAN and the company’s readiness for a potential commercial launch in 2026. He also highlighted Vera’s ambition to transform the practice of kidney medicine, aiming to help patients avoid dialysis or transplantation in the future. The positive sentiment is shared by Richard Lafayette, M.D., a primary investigator for the ORIGIN trials, who noted the significant impact of atacicept in reducing proteinuria. Additionally, Bonnie Schneider, Director and Cofounder of the IgA Nephropathy Foundation, acknowledged the progress in developing new treatments for patients, which could alleviate the clinical uncertainty and quality of life issues associated with IgAN. As the company prepares for its next steps with regulatory authorities, investors and patients alike are watching closely, with hopes that atacicept will become a new standard in IgAN therapy. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Sure, there are always opportunities in the stock market – but finding them feels more difficult now than a year ago. Unsure where to invest next? One of the best ways to discover new high-potential opportunities is to look at the top performing portfolios this year. ProPicks AI offers 6 model portfolios from Investing.com which identify the best stocks for investors to buy right now. For example, ProPicks AI found 9 overlooked stocks that jumped over 25% this year alone. The new stocks that made the monthly cut could yield enormous returns in the coming years. Is VERA one of them?

Click Subscribe #VeraTherapeutics #Phase3Trials #ClinicalTrials #BiotechNews #StockMarket

Yelak Biru: Phase 3 trials supporting FDA approvals in myeloma - OncoDaily Yelak Biru: Phase 3 trials supporting FDA approvals in myeloma / cancer, FDA, multiple myeloma, Myeloma, OncoDaily, Oncology, Phase 3 clinical trials, Yelak

Phase 3 trials supporting FDA approvals in myeloma - Yelak Biru
@northtxmsg.bsky.social
@fda.gov

oncodaily.com/insight/phas...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #MultipleMyeloma #Myeloma #FDA #Phase3Trials

AbbVie’s Tavapadon Shines in Phase 3 Trials for Parkinson’s Disease AbbVie’s investigational drug Tavapadon has achieved positive results in the Phase 3 TEMPO-2 trial, a critical milestone in developing new therapies for Parkinson’s disease. Designed as a flexible-dos...

www.linkedin.com/pulse/abbvie...

AbbVie’s Tavapadon Shines in Phase 3 Trials for Parkinson’s Disease

#ParkinsonsDisease #Tavapadon #AbbVie #NeurologicalDisorders #DopamineReceptors #Phase3Trials #ClinicalResearch #MotorSymptomRelief #Humanteconomy #Humantec

Pharma giants vie for oral GLP-1R approval - PharmaTimes Race to create first oral drug for obesity intensifies

#oralGLP1R #obesity #phase3trials #oralGLP1Rproducts #NovoNordisk #EliLilly #GLP1Rportfolios #obesitycategory #Wegovy #Saxenda #Zepbound #obesitymedication #obesityinjectables #Rybelsus #orforgliproncalcium #obesitylabelexpansion #obesitymarket #obesitylandscape
pharmatimes.com/news/pharma-...